Clinical trials: TACE
HCC
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable…
- Trial name
- NCT07099274
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
- Trial name
- EMERALD-3 (NCT05301842)
- Testing
- Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE)
- Where
- 171 sites in United States, Belgium and 20 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.
- Trial name
- NCT02638857
- Testing
- TACE, Dendritic Cell, lipiodol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Hepatocellular Carcinoma
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
This is a prospective, non-interventional, observational study evaluating the efficacy and immune microenvironment changes in Patients with Advanced Hepatocellular Carcinoma treated with TACE Combined with PD-1 Inhibitor.
- Trial name
- TASK-01-RW (NCT07100405)
- Testing
- PD-1 inhibitor, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Donafenib
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to…
- Trial name
- NCT05205629
- Testing
- Donafenib combined with TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Immunotherapy
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years after surgery.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Preoperative
- Trial name
- NCT05613478
- Testing
- Camrelizumab, Apatinib Mesylate, Radical surgery
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma, Hepatic Chemotherapy
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
This study intends to compare the efficacy of transcatheter arterial chemical embolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) for patients with intermediate-advanced huge hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
- Trial name
- NCT06641713
- Testing
- TACE, HAIC
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Sun Yat-sen University
Pain Control, Liver Cancer
Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures
This study is aimed at assessing the effectiveness of a novel liver specific nerve block in improving pain control during painful liver interventional radiology procedures including liver tumoral ablation and trans arterial…
- Trial name
- NCT04769713
- Testing
- Hepatic Hilar Nerve Block Needle placement, Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatocellular Carcinoma
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
- Trial name
- NCT05925413
- Testing
- Cadonilimab+TACE
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with…
- Trial name
- NCT06607120
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
This study used (cTACE or DEB-TACE + FOLFOX scheme HAIC) combined with PD-1 antibody camrelizumab and apatinib mesylas in the treatment of patients with advanced liver cancer, to evaluate the effectiveness and safety of the…
- Trial name
- NCT04479527
- Testing
- Camrelizumab
- Volunteers
- 34 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma, Liver Cancer
Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
The purpose of this study is to prospectively evaluate whether combined RFA and TACE (RFA-TACE) result in better survival outcomes than RFA alone in patients with HCC.
- Trial name
- RFA and TACE (NCT00554905)
- Testing
- Radiofrequency ablation, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated…
- Trial name
- NCT07682454
- Testing
- Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hepatocellular Carcinoma
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
This is a pilot study with a single arm in a single center assessing safety and efficacy of combination therapy of TACE and ablation and durvalumab.
- Trial name
- NCT04517227
- Testing
- Durvalumab, Transcatheter Hepatic Arterial Chemoembolization (TACE), Ablation
- Volunteers
- 30 people
- Sponsor
- Fudan University
Liver Cancer
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00109954
- Testing
- cisplatin, brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma Non-resectable, Chemoembolization, Therapeutic
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
- Trial name
- SERENADE-T (NCT03283956)
- Testing
- Patient records
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Metastatic Colorectal Cancer, mCRC
LifePearl-Iri Pharmacokinetic Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl microspheres loaded with irinotecan in the treatment of liver predominant mCRC by chemoembolization.
- Trial name
- NCT02547480
- Testing
- TACE with irinotecan loaded LifePearl
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Hepatocellular Carcinoma, Portal Vein Thrombosis
Neo-TACE-HAIC for PVTT-HCC
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for…
- Trial name
- NeoconceptC (NCT04181931)
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
Postoperative Adjuvant TACE, Hepatocellular Carcinoma.
Postoperative Adjuvant TACE Treatment in CK18 Positive Patients
To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the…
- Trial name
- NCT02724345
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital